Toulouse, France

Philippe Le Bouteiller

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Toulouse Cedex, FR (2015)
  • Toulouse, FR (2019)

Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Philippe Le Bouteiller: Innovator in Eye Disorder Treatments

Introduction

Philippe Le Bouteiller is a notable inventor based in Toulouse, France. He has made significant contributions to the field of medical research, particularly in the treatment of eye disorders. With a total of 2 patents, his work focuses on innovative therapeutic approaches.

Latest Patents

Le Bouteiller's latest patents include the development of anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis. This invention relates to the use of at least one anti-CD160 antibody, preferably a compound selected from the CL1-R2 monoclonal antibody, which may be obtained by the hybridoma CNCM 1-3204. The invention aims to prepare a drug designed to treat neovascular eye diseases.

Career Highlights

Throughout his career, Philippe Le Bouteiller has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Mablife. His research has contributed to advancements in medical treatments and has garnered attention in the scientific community.

Collaborations

Le Bouteiller has collaborated with notable professionals in his field, including Armand Bensussan. These partnerships have enhanced the impact of his research and innovations.

Conclusion

Philippe Le Bouteiller's work in developing anti-CD160 specific antibodies represents a significant advancement in the treatment of eye disorders. His contributions continue to influence the medical field and offer hope for patients suffering from neovascular eye diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…